University of California, San Francisco (UCSF) And OncoSec Medical Inc. Collaborate To Evaluate Investigational Combination Of ImmunoPulse And Anti-PD-1 Treatment

SAN DIEGO--(BUSINESS WIRE)--OncoSec Medical Inc. (OTCQB: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, has entered a clinical collaboration with the University of California, San Francisco (UCSF), to evaluate the safety, tolerability and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse (intratumoral IL-12) in metastatic melanoma.

Help employers find you! Check out all the jobs and post your resume.

Back to news